Cargando…
Upcoming immunotherapeutic combinations for B-cell lymphoma
After initial introduction for B-cell lymphomas as adjuvant therapies to established cancer treatments, immune checkpoint inhibitors and other immunotherapies are now integrated in mainstream regimens, both in adult and pediatric patients. We here provide an overview of the current status of combina...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326875/ https://www.ncbi.nlm.nih.gov/pubmed/35919738 http://dx.doi.org/10.1093/immadv/ltab001 |
_version_ | 1784757387108810752 |
---|---|
author | Greve, Patrick Meyer-Wentrup, Friederike A G Peperzak, Victor Boes, Marianne |
author_facet | Greve, Patrick Meyer-Wentrup, Friederike A G Peperzak, Victor Boes, Marianne |
author_sort | Greve, Patrick |
collection | PubMed |
description | After initial introduction for B-cell lymphomas as adjuvant therapies to established cancer treatments, immune checkpoint inhibitors and other immunotherapies are now integrated in mainstream regimens, both in adult and pediatric patients. We here provide an overview of the current status of combination therapies for B-cell lymphoma, by in-depth analysis of combination therapy trials registered between 2015–2020. Our analysis provides new insight into the rapid evolution in lymphoma treatment, as propelled by new additions to the treatment arsenal. We conclude with prospects on upcoming clinical trials which will likely use systematic testing approaches of more combinations of established chemotherapy regimens with new agents, as well as new combinations of immunotherapy and targeted therapy. Future trials will be set up as basket or umbrella-type trials to facilitate the evaluation of new drugs targeting specific genetic changes in the tumor or associated immune microenvironment. As such, lymphoma patients will benefit by receiving more tailored treatment that is based on synergistic effects of chemotherapy combined with new agents targeting specific aspects of tumor biology and the immune system. |
format | Online Article Text |
id | pubmed-9326875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-93268752022-08-01 Upcoming immunotherapeutic combinations for B-cell lymphoma Greve, Patrick Meyer-Wentrup, Friederike A G Peperzak, Victor Boes, Marianne Immunother Adv TrialsWatch After initial introduction for B-cell lymphomas as adjuvant therapies to established cancer treatments, immune checkpoint inhibitors and other immunotherapies are now integrated in mainstream regimens, both in adult and pediatric patients. We here provide an overview of the current status of combination therapies for B-cell lymphoma, by in-depth analysis of combination therapy trials registered between 2015–2020. Our analysis provides new insight into the rapid evolution in lymphoma treatment, as propelled by new additions to the treatment arsenal. We conclude with prospects on upcoming clinical trials which will likely use systematic testing approaches of more combinations of established chemotherapy regimens with new agents, as well as new combinations of immunotherapy and targeted therapy. Future trials will be set up as basket or umbrella-type trials to facilitate the evaluation of new drugs targeting specific genetic changes in the tumor or associated immune microenvironment. As such, lymphoma patients will benefit by receiving more tailored treatment that is based on synergistic effects of chemotherapy combined with new agents targeting specific aspects of tumor biology and the immune system. Oxford University Press 2021-02-09 /pmc/articles/PMC9326875/ /pubmed/35919738 http://dx.doi.org/10.1093/immadv/ltab001 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Immunology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | TrialsWatch Greve, Patrick Meyer-Wentrup, Friederike A G Peperzak, Victor Boes, Marianne Upcoming immunotherapeutic combinations for B-cell lymphoma |
title | Upcoming immunotherapeutic combinations for B-cell lymphoma |
title_full | Upcoming immunotherapeutic combinations for B-cell lymphoma |
title_fullStr | Upcoming immunotherapeutic combinations for B-cell lymphoma |
title_full_unstemmed | Upcoming immunotherapeutic combinations for B-cell lymphoma |
title_short | Upcoming immunotherapeutic combinations for B-cell lymphoma |
title_sort | upcoming immunotherapeutic combinations for b-cell lymphoma |
topic | TrialsWatch |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326875/ https://www.ncbi.nlm.nih.gov/pubmed/35919738 http://dx.doi.org/10.1093/immadv/ltab001 |
work_keys_str_mv | AT grevepatrick upcomingimmunotherapeuticcombinationsforbcelllymphoma AT meyerwentrupfriederikeag upcomingimmunotherapeuticcombinationsforbcelllymphoma AT peperzakvictor upcomingimmunotherapeuticcombinationsforbcelllymphoma AT boesmarianne upcomingimmunotherapeuticcombinationsforbcelllymphoma |